Announcement • Jan 13
Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana Validator Sharps Technology, Inc. announced the expansion of its relationship with Coinbase Institutional, through the launch of a jointly supported institutional-grade validator on the Solana network. The STSS Validator, operated by Coinbase and built on Coinbase Institutional's market-proven infrastructure stack, represents a meaningful shift for the company as it moves from a Solana treasury participant to a direct contributor to the security and decentralization of the network. Under this expanded initiative, STSS will delegate a portion of its SOL treasury holdings, currently more than 2 million SOL, to its newly established Coinbase-operated validator. The expanded relationship brings together Coinbase's institutional-grade infrastructure, security standards, and proven validator operations, to ensure high uptime, operational rigor, and long-term reliability. This expansion builds on the company's existing relationship with Coinbase Institutional, Through which STSS leverages Coinbase's custody, OTC, and operational infrastructure as part of its broader digital asset treasury strategy. With this validator launch, STSS becomes one of the first U.S.-listed companies to evolve from a treasury-only approach to an active infrastructure participant in blockchain development. Announcement • Oct 02
Sharps Technology, Inc. (NasdaqCM:STSS) announces an Equity Buyback for $100 million worth of its shares. Sharps Technology, Inc. (NasdaqCM:STSS) announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its shares. Announcement • Sep 02
Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $236.605575 million. Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $236.605575 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Announcement • Aug 29
Sharps Technology, Inc. announced that it has received $400 million in funding from a group of investors On August 28, 2025, the Sharps Technology, Inc. closed the transaction for the proceeds of $400 million. The transaction involves participation of FalconX, Phoenix Digital, Bastion Trading, RockawayX, Syncracy, Republic Digital, Arche Capital, Arrington Capital, Hypersphere, Quantstamp, FinTech Collective, CoinList Alpha, Primitive Ventures, Avenir Group, Luca Netz, Cube, and Saba Capital, and other investors. Announcement • Jul 06
Sharps Technology, Inc., Annual General Meeting, Aug 19, 2025 Sharps Technology, Inc., Annual General Meeting, Aug 19, 2025. Announcement • Apr 05
Nasdaq Notifies Sharps Technology Regarding Non-Compliance with the $2,500,000 Stockholders’ Equity Requirement On April 3, 2025, Sharps Technology Inc. (the ‘Company’), was notified by the staff (the ‘Staff’) of The Nasdaq Stock Market, LLC (‘Nasdaq’) that it was not in compliance with the $2,500,000 stockholders’ equity requirement for continued listing (the ‘Rule’) on The Nasdaq Capital Market. As reported in our Form 10-K for the fiscal year ended December 31, 2024, we reported stockholders’ equity of $1,996,129, and as of today, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. As the Company is already in the hearings process due to non-compliance with the minimum bid price requirement as previously reported in the Form 8-K filed on March 14, 2025, this will be treated as an additional and separate basis for delisting. The Company will present its views and its plans to regain compliance with respect to this additional deficiency at its Nasdaq hearing. There can be no assurance that the Company will be able to evidence compliance with the stockholders’ equity Rule or any other applicable requirements for continued listing on The Nasdaq Capital Market prior to the hearing. In the interim, the Company’s common stock and warrants will remain listed on Nasdaq under its existing symbols, ‘STSS’ and ‘STSSW’ while it awaits the hearing and Panel decision. Announcement • Mar 15
Sharps Technology Receives Non-Compliance letter from Nasdaq Regarding Minimum Bid Price Requirement As previously reported on October 16, 2024, the Company effected a 1-for-22 reverse stock split. In connection with same, the Staff (as defined below) determined that the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, and as a result, does not comply with Nasdaq Listing Rule 5550(a)(2). As such, on March 12, 2025, Sharps Technology, Inc. (the Company"), was notified by the staff (the Staff") of The Nasdaq Stock Market, LLC (Nasdaq") that it was not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market as the bid price of its securities had closed at less than $1.00 per share over the previous 30 consecutive business days. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company's securities will be delisted from the Nasdaq Capital Market unless the Company requests a hearing and appeals Nasdaq's determination. Accordingly, the Company will be timely filing a hearing request before the deadline which will automatically stay the delisting and suspension of the Company's securities pending the decision of the Nasdaq Hearings Panel (the Panel"). At the hearing, the Company intends to present its views and its plans to regain compliance with the minimum bid price rule to the Panel. There can be no assurance that the Company will be able to evidence compliance with the minimum bid price rules or any other applicable requirements for continued listing on The Nasdaq Capital Market prior to the hearing. In the interim, the Company expects its common stock and warrants will remain listed on Nasdaq under its existing symbols, STSS" and STSSW" while it awaits the hearing. Announcement • Jan 29
Sharps Technology, Inc. has completed a Composite Units Offering in the amount of $20 million. Sharps Technology, Inc. has completed a Composite Units Offering in the amount of $20 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 14,285,714
Price\Range: $1.4
Discount Per Security: $0.098
Security Name: Pre-Funded Units
Security Type: Equity/Derivative Unit
Securities Offered: 14,285,714
Price\Range: $1.3999
Discount Per Security: $0.9799 Announcement • Nov 11
Sharps Technology, Inc., Annual General Meeting, Dec 19, 2024 Sharps Technology, Inc., Annual General Meeting, Dec 19, 2024. Announcement • Sep 12
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ Meeting Sharps Technology, Inc. announced that the Company has secured approval from The Nasdaq Stock Market (‘Nasdaq’ or the ‘Exchange’) to maintain its listing, subject to conditions outlined the following. On September 9, 2024, Sharps Technology received a Determination Letter from Nasdaq confirming the Company's continued listing on the Exchange. This follows the August 13, 2024, hearing with the Nasdaq Hearings Panel, where the Company presented its compliance plan. At the August hearing, the Company’s senior management and outside counsel outlined its compliance plan to address a bid price deficiency. Previously, the Company had been granted an extension to resolve the deficiency, wherein the Company agreed to conduct a reverse split and obtained shareholder approval at a ratio of up to one share for eight. After obtaining shareholder approval, anew Exchange rule was proposed that would subject a company with a bid price deficiency to immediate delisting if the same company had experienced a bid price deficiency in the previous 12 months. As a result of this proposed rule, the Company determined to seek shareholder approval for a reverse split at a higher ratio to improve its chances of maintaining compliance with the bid price rule on a long-term basis. The Nasdaq Hearings Panel has granted the Company a brief exception to complete a reverse split and cure its bid price deficiency. Accordingly, the Company expects to complete a reverse stock split and regain compliance with the bid price rule within the exception period granted by the Panel. New Risk • Aug 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$7.20m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (44% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (145% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.20m market cap). Announcement • Jul 17
Sharps Technology, Inc. Receive Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) On July 12, 2023, The Nasdaq Stock Market LLC (Nasdaq") notified Sharps Technology, Inc. (the Company") that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(2) (the Nasdaq Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until January 8, 2024, to regain compliance with the Rule. Subsequently, on January 16, 2024, the Company was provided an additional 180 calendar day compliance period, or until July 8, 2024, to demonstrate compliance. Pursuant to Nasdaq's letter on July 9, 2024, the Company has not regained compliance with Listing Rule 5550(a)(2). Accordingly, its securities will be delisted from the Nasdaq Capital Market unless the Company requests a hearing and appeals Nasdaq's determination by July 16, 2024, the trading of the Company's common stock and warrants will be suspended at the opening of business on July 18, 2024. If the Company does not request a hearing, Nasdaq will complete the delisting by filing a Form 25-NSE Notification of Delisting with the U.S. Securities and Exchange Commission (the SEC") after applicable appeal periods have lapsed. The Company will be filing a hearing request before the deadline. In the interim, the Company expects its common stock and warrants will remain listed on NASDAQ under its existing symbols, STSS" and STSW" while it awaits the hearing. Announcement • Jul 10
Sharps Technology, Inc. announced a financing transaction Sharps Technology, Inc. announced a private placement that it will issue common shares of the company to receive funding on July 9, 2024. New Risk • Jun 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$19.6m market cap). New Risk • May 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 43% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$3.36m market cap). Minor Risk Shareholders have been diluted in the past year (34% increase in shares outstanding). Announcement • May 22
Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $14.1 million. Sharps Technology, Inc. has filed a Follow-on Equity Offering in the amount of $14.1 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 47,000,000
Price\Range: $0.3
Discount Per Security: $0.021 New Risk • Feb 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$5.09m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Jan 20
Listing Qualifications Department of the Nasdaq Stock Market LLC Determines Sharps Technology, Inc. Is Eligible for an Additional 180 Calendar Day Period, or Until July 8, 2024, to Regain Compliance As disclosed in a Current Report filed on Form 8-K on July 16, 2023, Sharps Technology, Inc. (the “Company”) had received a notice (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023 to July 11, 2023. The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten (10) consecutive business days, the Staff will provide written confirmation of compliance and this matter will be closed. On January 16, 2023, the Staff determined that the Company is eligible for an additional 180 calendar day period, or until July 8, 2024, to regain compliance. The Staff’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, the Staff will provide notice that its securities will be subject to delisting. The Company will continue to monitor the closing bid price of its Common Stock and will consider its available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement within the allotted compliance period. New Risk • Nov 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$8.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.8m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.34m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$4.4m net loss next year). Announcement • Nov 09
Sharps Technology, Inc., Annual General Meeting, Dec 19, 2023 Sharps Technology, Inc., Annual General Meeting, Dec 19, 2023, at 10:00 US Eastern Standard Time. Agenda: To consider and elect six directors, to serve until the Company’s 2024 annual meeting of stockholders or until their successors are duly elected and qualified; to approve, for purposes of complying with the provisions of those certain Securities Purchase Agreements dated September 27, 2023 (the SPA), the reduction of the potential minimum exercise price of warrants issued pursuant to the SPA from $0.64 to $0.0001, which is the par value of the common stock of the Company; to ratify the appointment of Manning Elliott LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; to approve proposed amendments to the Sharps Technology, Inc. 2023 Equity Incentive Plan, in substantially the form attached to the proxy statement as Annex A; and to consider other matters. New Risk • Oct 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 66% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$8.47m market cap). Announcement • Sep 28
Sharps Technology, Inc. announced that it expects to receive $5.6 million in funding Sharps Technology, Inc. announced a private placement of units at a price of $0.80 per unit for gross proceeds of $5,600,000 on September 27, 2023. The units consist of pre-funded warrants to purchase up to 2,581,479 common shares and common warrants to purchase 8,750,000 common shares at an exercise price of $0.64 per share. The exercise price per pre-funded warrant is $0.001 per share. The private placement warrants will be exercisable immediately subject to registration and will have a 5.5-year term from the initial exercise date. The transactions are expected to close on or about September 29, 2023, subject to the satisfaction of customary closing conditions. Announcement • Jul 16
Sharps Technology Receives a Notice from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market On July 12, 2023, Sharps Technology, Inc. received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023 to July 11, 2023. The Rules provide the company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, the Staff will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the minimum bid price requirement within the 180 day automatic cure period, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, apart from the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Staff will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff will provide notice that its securities will be subject to delisting. The Company will continue to monitor the closing bid price of its Common Stock and will consider its available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement within the allotted compliance period. Announcement • Jul 13
Sharps Technology Appoints Ben Scheu as Senior Director of Sales Sharps Technology, Inc. announced the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market. Mr. Scheu has held executive leadership positions in prominent healthcare companies and has demonstrated his ability to drive sales growth and develop effective commercial strategies. Prior to joining Sharps, Mr. Scheu served as President and CEO of Centor Inc., a pharmaceutical packaging manufacturing division of Gerresheimer with a complete line of regulatory compliant prescription containers for medication dispensing, packaging for robotic automation and standard and custom imprinted closures. At Centor, he oversaw significant revenue growth that led their company to achieve a market leading position in the prescription container and medication dispensing product segment. Additionally, Mr. Scheu served as COO of The Waddington Group, a division of Newell Brands (an $850 million per year disposable packaging manufacturer), President of B+H North America (a $400 million per year division of the AptarGroup), President of Rigid Closed Top (an ~$1 billion per year division of Berry Plastics Corporation), and executive sales and marketing roles at leading specialty market corporations. Mr. Scheu will be instrumental in leading Sharps’ marketing initiatives as the Company advances from research and development to commercial revenue. His initial focus will be leading sales efforts around Sharps’ commercial-ready Securegard®, a disposable smart safety syringe product offering with multiple configurations. Mr. Scheu will lead the efforts around commercialization and contracts with customers within the retail pharmacy space to support the efforts around the introduction of Sharps’ technology to healthcare customers, which include hospital networks. Sharps recently announced a qualification agreement with a major medical device company for its smart safety syringe technology that could drive increased commercial revenue in 2023. The agreement will begin with the 1mL and 3mL Securegard® product line and will be followed by Sologard® Luer lock syringes for larger volume drug applications. The qualification agreement will allow for the opportunity to create secondary sales agreements with additional key hospital networks, which Mr. Scheu will oversee. In conjunction with the vial-draw product launch, Sharps is also preparing for the commercialization of its next-generation polymer-based prefilled syringe systems, which will be the Company’s future growth driver. Technical and commercial resources will be added to Mr. Scheu’s prefilled product team, and Sharps will begin manufacturing from the Inject-EZ facility in Columbia, South Carolina. Through Mr. Scheu’s deep expertise in plastics operations and sales, he will play an integral role in supporting the partnership with Nephron Pharmaceuticals. New Risk • Jun 16
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.87m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.87m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Announcement • Feb 07
Sharps Technology, Inc. announced that it has received $3.8 million in funding On February 6, 2023, Sharps Technology, Inc. closed the transaction. Announcement • Feb 02
Sharps Technology, Inc. announced that it expects to receive $3.8 million in funding Sharps Technology, Inc. announced that it has raised $3.8 million. The Company will issue 2,248,521 units and pre-funded units at a purchase price of $1.69 per unit priced at-the-market under Nasdaq rules.The pre-funded units will be sold at the same price less the pre-funded warrant exercise price of $0.001. Each unit and pre-funded unit consist of one share of common stock (or pre-funded warrant) and one non-tradable warrant exercisable for one share of common stock at a price of $1.56. The warrants have a term of five years from the issuance date. Gross proceeds were $3.8 million before deducting fees to the placement agent and other offering expenses payable by the Company. The transaction is expected to close on or about February 3, 2023 Announcement • Feb 01
Sharps Technology, Inc. Ships First Containers of Safety Syringes to Nephron Pharmaceuticals for Commercialization Sharps Technology, Inc. announced the first shipments of product from its wholly owned manufacturing facility in Hungary to Nephron Pharmaceuticals to advance the Company's first commercial operations. Securegard is the first product that will be available to the market through the Company's collaboration with Nephron and will be introduced through Nephron’s network of more than 3,000 customers. Securegard is a vial draw product with innovative product features for safety, ultra-low waste and non-reuse that has been approved by the Food and Drug Administration (FDA), the World Health Organization (WHO), and received a CE Mark, facilitating global sales. Initial shipments will total 1.3 million 1-mililiter (1mL) units by February and will increase with additional volume and product configurations as sales commence. Announcement • Jan 12
Sharps Technology Inc. to Introduces New Specialized Prefillable Syringe Systems in 2023 Sharps Technology, Inc. announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina. Sharps' specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment. Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+ million units, with additional capacities that can be scaled by 2025 with an additional 100 million units annually. Products will be manufactured utilizing Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps' PFS systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Jul 15
Sharps Technology, Inc. (NasdaqCM:STSS) completed the acquisition of Safegard Medical (Hungary) Kft. from Numan Holding Ltd. Sharps Technology, Inc. (NasdaqCM:STSS) agreed to acquire Safegard Medical (Hungary) Kft. from Numan Holding Ltd. for $2.5 million on July 8, 2022. The purchase price of $2.5 million was released to Numan. Sharps Technology previously issued 28,571 shares of common stock and 35,714 warrants to purchase common stock at $7.00 per share to Numan. The Acquisition consisted primarily of Safegard’s syringe manufacturing facility in Hungary and the land on which it is located, as well as certain equipment in the facility. Sharps Technology, Inc. (NasdaqCM:STSS) completed the acquisition of Safegard Medical (Hungary) Kft. from Numan Holding Ltd. on July 14, 2022. Board Change • Jun 01
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • May 13
Independent Non-Executive Director recently bought US$140k worth of stock On the 9th of May, Timothy Ruemler bought around 112k shares on-market at roughly US$1.25 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$263k more in shares than they have sold in the last 12 months. Board Change • May 02
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Co-Chairman of the Board Soren Christiansen is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 20
Brenda Baird Simpson and Jason Monroe Elects to Sharps Technology, Inc.'s Board of Directors On April 15, 2022, Brenda Baird Simpson and Jason Monroe were elected to the Sharps Technology, Inc.'s board of directors. Ms. Simpson will serve on the audit committee of the Company’s board of directors, and Mr. Monroe will serve on the audit, compensation and nominating committees. Announcement • Apr 16
Sharps Technology, Inc. has completed an IPO in the amount of $15.9375 million. Sharps Technology, Inc. has completed an IPO in the amount of $15.9375 million.
Security Name: Common Units
Security Type: Equity/Derivative Unit
Securities Offered: 3,750,000
Price\Range: $4.25
Discount Per Security: $0.34 
